ADIDAS IS WINNING THE MARATHON SHOE WAR. NOW COMES THE BUSINESS TEST.

By Hugh Mercer

The $500 Adizero Adios Pro Evo 3 has given adidas a commanding presence at the front of major marathons. The bigger opportunity is turning that credibility into demand across the running shoes it can sell at scale.

For much of the past decade, Nike set the agenda in marathon footwear. The Vaporfly and Alphafly helped establish the modern supershoe market and forced competitors to respond.

Now adidas has a flagship capable of changing that conversation. But an exceptional racing product is only the opening argument. The commercial test is whether runners who admire it become customers of the wider Adizero franchise.

The performance advantage

At London in April, Sabastian Sawe wore the Evo 3 to run 1:59:30, becoming the first runner to break two hours in an official marathon. London Marathon Events

Runner’s World reports Evo 3 wearers won seven of eight open titles across London, Sydney, Berlin and Chicago. Runner’s World

The shoe’s specifications help explain the attention. adidas says it averages 97 grams in a UK size 8.5, is 30% lighter than its predecessor, delivers 11% greater forefoot energy return and improves running economy by 1.6% under its testing conditions. Those are manufacturer claims, not a promise of the same improvement for every runner. adidas launch announcement

Chicago supplied a sharp illustration of the rivalry: Nike held the official footwear and apparel partnership, while adidas athletes Amos Kipruto and Hawi Feysa won the open races. Event sponsorship and elite victories reach consumers differently. adidas now has a compelling performance story to take into stores. World Athletics Chicago results

There is already a business signal

This is not a commercial opportunity supported only by finish-line photographs. adidas reported that its Running business grew around 30% in the second quarter of 2026. The company also linked Adizero’s credibility to continued demand for the Evo SL. adidas second quarter results

That figure gives the argument substance. The company is growing in running while its elite racing product attracts attention. It does not, however, isolate Evo 3 sales, establish how much growth the shoe caused or disclose the profitability of the Adizero franchise.

The distinction matters because the useful question is no longer simply whether adidas can make a winning marathon shoe. It is whether the company can sustain that momentum across products, price points and successive buying cycles.

The opportunity below $500

The US adidas site lists another Evo 3 release for October 29 at $500. Its strategic importance extends beyond the revenue from that allocation. adidas US product page

Below it sits the $275 Adios Pro 5, which adidas describes as incorporating technology developed for the Evo 3. At $150, the Evo SL offers a lower-priced route into the Adizero performance-running family. These are US retail prices. Adios Pro 5 announcement adidas US range

That range creates several opportunities to convert interest into a purchase. A runner attracted by the flagship’s achievements might choose the Adios Pro 5 for a marathon. Another might try the Evo SL for training without spending $500 on a specialist racing shoe.

The commercial logic is straightforward: the flagship attracts attention, while more accessible products give a broader audience somewhere to spend. The existence of that ladder does not prove customers are moving through it. That is the behavior adidas needs to build and retailers need to see.

Fit, availability and the experience of running in those shoes will determine whether the initial interest survives the purchase. A spectacular marathon result can start the conversation. It cannot replace a product that works for the customer.

What would make the advantage last

The strongest evidence would be sustained demand across Adizero, healthy sales at full price and runners returning to the franchise when their shoes need replacing. Specialty retailers would provide another useful test: are customers asking for adidas, trying it alongside rivals and buying it?

None of those outcomes can be read directly from elite results. Sponsored athletes are not a representative sample of shoppers, and a $500 price tag does not reveal a shoe’s margin. Product-level sales, costs and profitability remain necessary to judge the economics.

Nike, ASICS, HOKA, On and other competitors will keep challenging for those same customers. A technical lead can narrow as new products arrive. The more durable advantage would be a larger base of runners who trust adidas for their next purchase, not just their next race-day headline.

The Evo 3 has strengthened adidas’ case at the elite level. Its reported Running growth suggests there is commercial momentum too. The next test is whether the company can turn this product cycle into a lasting advantage in the running footwear business.